Soluble CD40 ligand-activated human peripheral B cells as surrogated antigen presenting cells: A preliminary approach for anti-HBV immunotherapy

Virol J. 2010 Dec 23:7:370. doi: 10.1186/1743-422X-7-370.

Abstract

Background: We aimed to clarify whether soluble CD40 ligand (sCD40L) activated B cells may be loaded with HBcAg18-27 peptide and served as antigen-producing cells (APCs) to induce HBV-specific cytolytic T lymphocytes (CTLs).

Results: Human B cells could be cultured in the presence of sCD40L up to 54 days, and the proportion of B cells in the S phase increased from 0% to 8.34% in the culture. The expression of CD80, CD86, major histocompatibility complex (MHC) classes I and II molecules on the sCD40L-activated B cell was significantly increased after long-time culture. Cytometry and fluorescence microscopy showed that more than 98% sCD40L-activated B cells were loaded by the HBcAg peptide. Furthermore, the peptide-pulsed activated B cells could induce HBcAg18-27 specific CTLs.

Conclusions: Our results demonstrate that sCD40L-activated B cells may function as APCs and induce HBV-specific CTLs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigen-Presenting Cells / immunology*
  • B-Lymphocytes / immunology*
  • CD40 Ligand / immunology*
  • Flow Cytometry
  • Gene Expression Regulation
  • Humans
  • Immunotherapy*
  • Lymphocyte Activation / genetics
  • Lymphocyte Activation / immunology*
  • T-Lymphocytes, Cytotoxic / immunology

Substances

  • CD40 Ligand